Last reviewed · How we verify

Standard Fresh Whole Blood

Johns Hopkins University · Phase 3 active Biologic

Standard Fresh Whole Blood is a Blood product Biologic drug developed by Johns Hopkins University. It is currently in Phase 3 development for Acute hemorrhage requiring massive transfusion, Severe anemia with hemodynamic instability, Trauma with life-threatening blood loss.

Standard Fresh Whole Blood provides immediate restoration of oxygen-carrying capacity, clotting factors, and circulating volume in acute hemorrhage or severe anemia.

Standard Fresh Whole Blood provides immediate restoration of oxygen-carrying capacity, clotting factors, and circulating volume in acute hemorrhage or severe anemia. Used for Acute hemorrhage requiring massive transfusion, Severe anemia with hemodynamic instability, Trauma with life-threatening blood loss.

At a glance

Generic nameStandard Fresh Whole Blood
SponsorJohns Hopkins University
Drug classBlood product
ModalityBiologic
Therapeutic areaHematology/Transfusion Medicine
PhasePhase 3

Mechanism of action

Fresh whole blood contains red blood cells for oxygen transport, plasma proteins including clotting factors for hemostasis, and platelets for primary hemostasis, along with electrolytes and other blood components. It is used in emergency transfusion settings to rapidly restore blood volume and function when component therapy is unavailable or when massive transfusion is required. This is a cellular/biological product rather than a drug with a specific molecular mechanism.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Standard Fresh Whole Blood

What is Standard Fresh Whole Blood?

Standard Fresh Whole Blood is a Blood product drug developed by Johns Hopkins University, indicated for Acute hemorrhage requiring massive transfusion, Severe anemia with hemodynamic instability, Trauma with life-threatening blood loss.

How does Standard Fresh Whole Blood work?

Standard Fresh Whole Blood provides immediate restoration of oxygen-carrying capacity, clotting factors, and circulating volume in acute hemorrhage or severe anemia.

What is Standard Fresh Whole Blood used for?

Standard Fresh Whole Blood is indicated for Acute hemorrhage requiring massive transfusion, Severe anemia with hemodynamic instability, Trauma with life-threatening blood loss.

Who makes Standard Fresh Whole Blood?

Standard Fresh Whole Blood is developed by Johns Hopkins University (see full Johns Hopkins University pipeline at /company/johns-hopkins-university).

What drug class is Standard Fresh Whole Blood in?

Standard Fresh Whole Blood belongs to the Blood product class. See all Blood product drugs at /class/blood-product.

What development phase is Standard Fresh Whole Blood in?

Standard Fresh Whole Blood is in Phase 3.

What are the side effects of Standard Fresh Whole Blood?

Common side effects of Standard Fresh Whole Blood include Transfusion reaction (acute hemolytic), Transfusion-related acute lung injury (TRALI), Transfusion-associated circulatory overload (TACO), Infection transmission risk, Alloimmunization.

Related